Companies › Xencor
8 active drug programs in 9 registered trials: 8 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| vudalimab (XmAb20717) Bispecific monoclonal antibody targeting CTLA-4 and TIGIT | CTLA4, TIGIT | Phase 2 | Ovarian Cancer | – |
| XmAb819 Monoclonal bispecific antibody | – | Phase 1 | Clear Cell Renal Cell Carcinoma | Feb 2027 |
| XmAb412 Monoclonal Bispecific Antibody | – | Phase 1 | Not Applicable - Healthy Adult Participants | May 2027 |
| XmAb541 Monoclonal bispecific antibody | – | Phase 1 | Ovarian Cancer | Dec 2027 |
| XmAb942 Antibody | – | Phase 1 | Ulcerative Colitis (UC) | Dec 2027 |
| Plamotamab CD40-engaging bispecific antibody | CD40 | Phase 1 | Rheumatoid Arthritis | Jun 2028 |
| XmAb657 | – | Phase 1 | Healthy | Oct 2028 |
| XmAb808 Monoclonal bispecific antibody | – | Phase 1 | Ovarian Cancer | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05032040 | vudalimab (XmAb20717) | Phase 2 | Ovarian Cancer | Oncology | Oct 2025 |
| NCT05433142 | XmAb819 | Phase 1 | Clear Cell Renal Cell Carcinoma | Oncology | Feb 2027 |
| NCT07713485 | XmAb412 | Phase 1 | Not Applicable - Healthy Adult Participants | Immunology | May 2027 |
| NCT06276491 | XmAb541 | Phase 1 | Ovarian Cancer | Oncology | Dec 2027 |
| NCT06619990 | XmAb942 | Phase 1 | Ulcerative Colitis (UC) | Immunology | Dec 2027 |
| NCT07230353 | Plamotamab | Phase 1 | Rheumatoid Arthritis | Immunology | Jun 2028 |
| NCT07284797 | XmAb657 | Phase 1 | Healthy | Immunology | Oct 2028 |
| NCT07593092 | XmAb541 | Phase 1 | Ovarian Cancer | Oncology | Dec 2028 |
| NCT07593092 | XmAb808 | Phase 1 | Ovarian Cancer | Oncology | Dec 2028 |
Cash of $60m on 2026-09-30; operating cash outflow about $162m a year; runway about 4 months at that burn, to Feb 2027
Press releases filed as 8-K in the last year:
MacroGenics Miltenyi Biomedicine TScan Therapeutics Agenus Huabo Biopharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.